VEGFA and neoplasm: Bevacizumab is a humanized monoclonal IgG1 antibody targeting the vascular endothelial growth factor (VEGF); therefore, it prevents the binding to the VEGF receptor exhibiting many different anti-angiogenic and anti-tumor effects.